Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore (ECOR) announced positive top-line results from the SAVIOR-1 study, exploring non-invasive vagus nerve stimulation (nVNS) in COVID-19 patients. Conducted in Spain, the study involved 110 hospitalized patients and evaluated the safety and feasibility of nVNS alongside standard care. Results showed a significant decrease in C-Reactive Protein (CRP) in the nVNS group (-59.08 vs. -27.83; p0.01). While modest improvements were noted in clinical endpoints, further data will be submitted for peer review. The findings suggest nVNS may enhance recovery in severe COVID-19 cases.
electroCore, Inc. (Nasdaq: ECOR) has received regulatory approval from Health Canada for the gammaCore Sapphire products, intended for the prevention and therapeutic treatment of migraines and cluster headaches. These products will be exclusively distributed by RSK Medical Inc. under a three-year agreement. The approval is a significant milestone for electroCore as it expands its market presence. The device offers a non-invasive treatment option, promoting better patient outcomes without the side effects common with traditional medications.
electroCore (Nasdaq: ECOR), a bioelectronic medicine company, has announced a partnership with Silvert Medical to distribute its gammaCore Sapphire non-invasive vagus nerve stimulator in Belgium, Luxembourg, the Netherlands, and France. This agreement, effective for three years, marks a significant step in expanding the reach of gammaCore, aimed at treating chronic migraine and cluster headaches. Eric Silvert, Managing Director of Silvert Medical, expressed enthusiasm about this collaboration, while electroCore's VP of European Operations emphasized their goal in enhancing patient care in these territories.
electroCore, Inc. (Nasdaq: ECOR) has shared insights on managing COVID-19 symptoms as new cases rise, with 97,309 reported. Chief Medical Officer Peter Staats highlights at-home strategies for symptoms like confusion, migraines, cough, and trouble breathing. The gammaCore Sapphire™ (nVNS) device is mentioned for migraine relief and asthma-related symptoms in COVID patients. Recommendations include hydration, rest, and consulting healthcare providers for persistent issues. The press release emphasizes continued health precautions even post-vaccination.
electroCore, Inc. (Nasdaq: ECOR) reported a 46% increase in full-year 2020 net sales, totaling approximately $3.5 million compared to $2.4 million in 2019. The fourth quarter saw net sales of around $928,000, up 38% year-over-year. The company also reduced net cash usage to $3.7 million in Q4 2020 from $4.1 million in Q3 2020. Cash and equivalents were $22.6 million as of December 31, 2020. The establishment of a unique reimbursement code and multiple distribution agreements highlight significant operational progress.
electroCore (Nasdaq: ECOR) will announce its financial results for Q4 and the fiscal year ending December 31, 2020, after market close on March 11, 2021. A conference call is scheduled for 4:30 PM ET for management to discuss the results. The company focuses on bioelectronic medicine, particularly through non-invasive vagus nerve stimulation therapy, addressing conditions such as cluster headaches and migraines in adults and adolescents.
electroCore, Inc. (Nasdaq: ECOR) announced participation in two investor conferences. The first is the H.C. Wainwright Global Life Sciences Conference, featuring a pre-recorded fireside chat available from March 9, 2021, at 7:00 a.m. ET. The second is the M Vest LLC and Maxim Group LLC Emerging Growth Virtual Conference, starting with a presentation on March 17, 2021, at 9:00 a.m. ET. Both events will include virtual investor meetings and replays will be accessible on the company's website for 90 days.
electroCore, Inc. (Nasdaq: ECOR) has entered a three-year agreement with Medistar, making them the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator in Australia. This follows the Australian Therapeutic Goods Administration's approval for the sale of gammaCore products. The partnership aims to provide patients suffering from primary headache disorders with access to this innovative therapy. Medistar will officially launch gammaCore at the ANZHS Headache Annual Scientific Meeting on March 13-14, 2021.
electroCore, Inc. (Nasdaq: ECOR) has announced the completion of patient enrollment for its SAVIOR-1 study, which evaluates the impact of non-invasive vagus nerve stimulation (nVNS) on respiratory symptoms in COVID-19 patients. This significant step aims to uncover potential therapeutic benefits for respiratory distress caused by the virus. Dr. Carlos Tornero highlights the promise of vagus nerve stimulation in treating respiratory functions. The study is backed by electroCore and underscores the ongoing search for effective COVID-19 treatments.
electroCore (Nasdaq: ECOR) announced that gammaCore will remain listed in the NHS Supply Chain catalogue for an additional two years, extending its availability through June 3, 2023. This listing allows NHS trusts to continuously procure gammaCore Sapphire™ (nVNS), facilitating better access for patients in the UK needing non-invasive vagus nerve stimulation for migraine and cluster headache treatments. The inclusion is pivotal for ensuring that this innovative therapy is accessible and cost-effective for healthcare organizations amid budgetary constraints.